Cardarine vs Stenabolic: A Detailed Comparison
Cardarine (GW-501516) and Stenabolic (SR9009) are popular topics in performance enhancement discussions but are not Selective Androgen Receptor Modulators (SARMs). Understanding their intended uses and mechanisms offers insight into their distinct roles.
What Was Cardarine Designed To Do?
Developed by GlaxoSmithKline, Cardarine acts as a PPARδ agonist. It was created to increase the body's ability to burn fatty acids, potentially improving physical endurance and performance. Cardarine advanced to clinical trials but was discontinued due to safety concerns. Its mechanism involves activating the PPARδ pathway, which plays a vital role in energy use and fat metabolism.
What Was Stenabolic Designed To Do?
Stenabolic functions as a REV-ERB agonist and remains in preclinical research. It aims to affect circadian rhythms and metabolic functions, potentially boosting endurance and reducing fat storage. Stenabolic influences the body's internal clock, thereby affecting energy production and overall metabolism.
Key Differences
| Aspect | Cardarine | Stenabolic |
|---|---|---|
| Compound Class | PPARδ Agonist | REV-ERB Agonist |
| Mechanism | Enhances fatty acid oxidation | Regulates circadian metabolism |
| Clinical Progression | Reached and discontinued in trials | Stays at preclinical stage |
| Human Data | Data from halted trials | Limited to animal studies |
What Actually Separates Them?
The primary distinction between Cardarine and Stenabolic is their clinical development status. Cardarine proceeded to human trials but was eventually stopped, while SR9009 has not moved beyond animal research.
Legal & Disclaimer
It's important to note that neither Cardarine nor Stenabolic is approved for human use by any regulatory body. They are intended solely for research purposes.